Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA. Clamp AR, et al. Among authors: gabra h. Lancet. 2019 Dec 7;394(10214):2084-2095. doi: 10.1016/S0140-6736(19)32259-7. Epub 2019 Nov 29. Lancet. 2019. PMID: 31791688 Free PMC article. Clinical Trial.
A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
Ang JE, Shah RN, Everard M, Keyzor C, Coombes I, Jenkins A, Thomas K, A'Hern R, Jones RL, Blake P, Gabra H, Hall G, Gore ME, Kaye SB. Ang JE, et al. Among authors: gabra h. Ann Oncol. 2009 Nov;20(11):1787-93. doi: 10.1093/annonc/mdp193. Epub 2009 Jun 19. Ann Oncol. 2009. PMID: 19542250 Free article. Clinical Trial.
Promising molecular targets in ovarian cancer.
Blagden S, Gabra H. Blagden S, et al. Among authors: gabra h. Curr Opin Oncol. 2009 Sep;21(5):412-9. doi: 10.1097/CCO.0b013e32832eab1f. Curr Opin Oncol. 2009. PMID: 19553815 Review.
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series.
Agarwal R, Gourley C, Perren TJ, Reed N, Parkin DE, Carty K, Rustin GJ, Gabra H, Paul J, Gore ME, Kaye SB; Scottish Gynecological Cancers Trials Group. Agarwal R, et al. Among authors: gabra h. Eur J Cancer. 2010 Jul;46(11):2020-6. doi: 10.1016/j.ejca.2010.03.006. Epub 2010 Apr 13. Eur J Cancer. 2010. PMID: 20395128 Clinical Trial.
Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
Ledermann JA, Gabra H, Jayson GC, Spanswick VJ, Rustin GJ, Jitlal M, James LE, Hartley JA. Ledermann JA, et al. Among authors: gabra h. Clin Cancer Res. 2010 Oct 1;16(19):4899-905. doi: 10.1158/1078-0432.CCR-10-0832. Epub 2010 Aug 18. Clin Cancer Res. 2010. PMID: 20719935 Free PMC article. Clinical Trial.
216 results